The excellent prognosis associated with most low-risk cancers combined with the potential for avoiding treatment side effects make active surveillance a promising alternative to more intensive approaches. But achieving widespread adoption will require further work.
No takes yet. Share an insight, caveat, or question.
Haymart et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: